Automated GMP Manufacturing of γδ-Enriched Tumor-Reactive T Cells using CliniMACS Prodigy: Enabling Decentralized Cell Therapy Production for AML Relapse Prevention

• Generation of tumor-reactive T-cell products from healthy donors and AML patients
• Composition, characterization and functionality of tumor-reactive T-cell products
• Implications for clinical translation and future development

Speakers:

Elena Maryamchik

Director of Cell Therapy Laboratory

Memorial Sloan Kettering Cancer Center